Data Updates in the Treatment of Resectable Cutaneous Squamous Cell Carcinoma (CSCC) - Episode 14

CSCC: Escalating Therapy for High-risk Patients

, , ,

Dr Vishal Patel shares a surgeon’s perspective on MDC, followed by a discussion on how intensifying treatment after surgery may improve outcomes for higher-risk patients with CSCC.

EP. 1: Cutaneous Squamous Cell Carcinoma: Incidence and Risk Factors
EP. 2: Available Staging Systems for Cutaneous Squamous Cell Carcinoma
EP. 3: Optimal Risk Stratification in Patients With Cutaneous Squamous Cell Carcinoma
EP. 4: Defining Resectability in CSCC
EP. 5: Staging and Risk Stratification’s Impact on Treatment Approach in CSCC
EP. 6: Real World Experience With Resectable Cutaneous Squamous Cell Carcinoma
EP. 7: Evolving Treatment Paradigm of Resectable CSCC
EP. 8: Clinical Experience With Neoadjuvant IO Therapy in Melanoma
EP. 9: Lessons Learned in Other Cancers and Suggested Endpoints in Future Trials
EP. 10: Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates
EP. 11: CSCC: Translating Cemiplimab Data Into Practice
EP. 12: Other Emerging Treatment Modalities in Cutaneous Squamous Cell Carcinoma
EP. 13: Best Practices in Multidisciplinary Care for CSCC
Now Viewing
EP. 14: CSCC: Escalating Therapy for High-risk Patients
EP. 15: Practical Advice on the Evolving Management of CSCC

Related Content:

Data Updates in the Treatment of Resectable Cutaneous Squamous Cell Carcinoma (CSCC)Moffitt Cancer CenterFlorida Cancer Specialists & Research InstituteUPMC Hillman Cancer CenterOncLive Peer Exchange® Melanoma & Skin Cancer
FDA Grants Breakthrough Therapy Designation to RP1 Plus Nivolumab in Advanced Melanoma
Neoadjuvant Therapy NCCN Recommendations Take the Melanoma Field in a New Direction
Dr Forsyth on a Phase 1 Study Evaluating Intrathecal cDC1s in Leptomeningeal Disease